Industry Research Reports

Home > Reports > Service & Software > AI-based Antibody Development Platform- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

AI-based Antibody Development Platform- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Service & Software

Published Date: 2024-06-15

Pages: 82 Pages

Report ld: 3197382

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

A critical aspect of a successful pandemic response is expedient antibody discovery, manufacturing and deployment of effective lifesaving treatments to patients around the world. However, typical drug discovery and development is a lengthy multi-step process that must align drug efficacy with multiple developability criteria and can take years to complete. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of therapeutics, increasing their activity and safety as well as decreasing their development time and manufacturing costs. Artificial intelligence stands at the forefront of transforming antibody development. AI and machine learning (ML) algorithms can analyze vast datasets, uncover patterns, and predict outcomes with a speed and accuracy unattainable by human researchers.

The global market for AI-based Antibody Development Platform was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of %during the forecast period 2024-2030.

North American market for AI-based Antibody Development Platform was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for AI-based Antibody Development Platform was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for AI-based Antibody Development Platform was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of AI-based Antibody Development Platform include Kyinno Biotechnolog, XtalPi Inc, DenovAI Biotech, immunitoAI Private Limited, EVQLV, Creative Biolabs, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

The AI-based Antibody Development Platform market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AI-based Antibody Development Platform.

MARKET SEGMENTATION

By Company

Kyinno Biotechnolog
XtalPi Inc
DenovAI Biotech
immunitoAI Private Limited
EVQLV
Creative Biolabs

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Antibody Generation and Screening
Discovery and Target Recognition
Engineering and Optimization
Other

Segment by Application

Pharmaceutical
Biotechnology
Academic Research
Others

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of AI-based Antibody Development Platform company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of AI-based Antibody Development Platform in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of AI-based Antibody Development Platform in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 AI-based Antibody Development Platform Product Introduction

1.2 Global AI-based Antibody Development Platform Market Size Forecast (2019-2030)

1.3 AI-based Antibody Development Platform Market Trends & Drivers

1.3.1 AI-based Antibody Development Platform Industry Trends

1.3.2 AI-based Antibody Development Platform Market Drivers & Opportunity

1.3.3 AI-based Antibody Development Platform Market Challenges

1.3.4 AI-based Antibody Development Platform Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global AI-based Antibody Development Platform Players Revenue Ranking (2023)

2.2 Global AI-based Antibody Development Platform Revenue by Company (2019-2024)

2.3 Key Companies AI-based Antibody Development Platform Manufacturing Base Distribution and Headquarters

2.4 Key Companies AI-based Antibody Development Platform Product Offered

2.5 Key Companies Time to Begin Mass Production of AI-based Antibody Development Platform

2.6 AI-based Antibody Development Platform Market Competitive Analysis

2.6.1 AI-based Antibody Development Platform Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by AI-based Antibody Development Platform Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AI-based Antibody Development Platform as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Antibody Generation and Screening

3.1.2 Discovery and Target Recognition

3.1.3 Engineering and Optimization

3.1.4 Other

3.2 Global AI-based Antibody Development Platform Sales Value by Type

3.2.1 Global AI-based Antibody Development Platform Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global AI-based Antibody Development Platform Sales Value, by Type (2019-2030)

3.2.3 Global AI-based Antibody Development Platform Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Pharmaceutical

4.1.2 Biotechnology

4.1.3 Academic Research

4.1.4 Others

4.2 Global AI-based Antibody Development Platform Sales Value by Application

4.2.1 Global AI-based Antibody Development Platform Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global AI-based Antibody Development Platform Sales Value, by Application (2019-2030)

4.2.3 Global AI-based Antibody Development Platform Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global AI-based Antibody Development Platform Sales Value by Region

5.1.1 Global AI-based Antibody Development Platform Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global AI-based Antibody Development Platform Sales Value by Region (2019-2024)

5.1.3 Global AI-based Antibody Development Platform Sales Value by Region (2025-2030)

5.1.4 Global AI-based Antibody Development Platform Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America AI-based Antibody Development Platform Sales Value, 2019-2030

5.2.2 North America AI-based Antibody Development Platform Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe AI-based Antibody Development Platform Sales Value, 2019-2030

5.3.2 Europe AI-based Antibody Development Platform Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific AI-based Antibody Development Platform Sales Value, 2019-2030

5.4.2 Asia Pacific AI-based Antibody Development Platform Sales Value by Region (%), 2023 VS 2030

5.5 South America

5.5.1 South America AI-based Antibody Development Platform Sales Value, 2019-2030

5.5.2 South America AI-based Antibody Development Platform Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa AI-based Antibody Development Platform Sales Value, 2019-2030

5.6.2 Middle East & Africa AI-based Antibody Development Platform Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions AI-based Antibody Development Platform Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions AI-based Antibody Development Platform Sales Value, 2019-2030

6.3 United States

6.3.1 United States AI-based Antibody Development Platform Sales Value, 2019-2030

6.3.2 United States AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

6.3.3 United States AI-based Antibody Development Platform Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe AI-based Antibody Development Platform Sales Value, 2019-2030

6.4.2 Europe AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe AI-based Antibody Development Platform Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China AI-based Antibody Development Platform Sales Value, 2019-2030

6.5.2 China AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

6.5.3 China AI-based Antibody Development Platform Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan AI-based Antibody Development Platform Sales Value, 2019-2030

6.6.2 Japan AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan AI-based Antibody Development Platform Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea AI-based Antibody Development Platform Sales Value, 2019-2030

6.7.2 South Korea AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea AI-based Antibody Development Platform Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia AI-based Antibody Development Platform Sales Value, 2019-2030

6.8.2 Southeast Asia AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia AI-based Antibody Development Platform Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India AI-based Antibody Development Platform Sales Value, 2019-2030

6.9.2 India AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

6.9.3 India AI-based Antibody Development Platform Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Kyinno Biotechnolog

7.1.1 Kyinno Biotechnolog Profile

7.1.2 Kyinno Biotechnolog Main Business

7.1.3 Kyinno Biotechnolog AI-based Antibody Development Platform Products, Services and Solutions

7.1.4 Kyinno Biotechnolog AI-based Antibody Development Platform Revenue (US$ Million) & (2019-2024)

7.1.5 Kyinno Biotechnolog Recent Developments

7.2 XtalPi Inc

7.2.1 XtalPi Inc Profile

7.2.2 XtalPi Inc Main Business

7.2.3 XtalPi Inc AI-based Antibody Development Platform Products, Services and Solutions

7.2.4 XtalPi Inc AI-based Antibody Development Platform Revenue (US$ Million) & (2019-2024)

7.2.5 XtalPi Inc Recent Developments

7.3 DenovAI Biotech

7.3.1 DenovAI Biotech Profile

7.3.2 DenovAI Biotech Main Business

7.3.3 DenovAI Biotech AI-based Antibody Development Platform Products, Services and Solutions

7.3.4 DenovAI Biotech AI-based Antibody Development Platform Revenue (US$ Million) & (2019-2024)

7.3.5 DenovAI Biotech Recent Developments

7.4 immunitoAI Private Limited

7.4.1 immunitoAI Private Limited Profile

7.4.2 immunitoAI Private Limited Main Business

7.4.3 immunitoAI Private Limited AI-based Antibody Development Platform Products, Services and Solutions

7.4.4 immunitoAI Private Limited AI-based Antibody Development Platform Revenue (US$ Million) & (2019-2024)

7.4.5 immunitoAI Private Limited Recent Developments

7.5 EVQLV

7.5.1 EVQLV Profile

7.5.2 EVQLV Main Business

7.5.3 EVQLV AI-based Antibody Development Platform Products, Services and Solutions

7.5.4 EVQLV AI-based Antibody Development Platform Revenue (US$ Million) & (2019-2024)

7.5.5 EVQLV Recent Developments

7.6 Creative Biolabs

7.6.1 Creative Biolabs Profile

7.6.2 Creative Biolabs Main Business

7.6.3 Creative Biolabs AI-based Antibody Development Platform Products, Services and Solutions

7.6.4 Creative Biolabs AI-based Antibody Development Platform Revenue (US$ Million) & (2019-2024)

7.6.5 Creative Biolabs Recent Developments

8 Industry Chain Analysis

8.1 AI-based Antibody Development Platform Industrial Chain

8.2 AI-based Antibody Development Platform Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 AI-based Antibody Development Platform Sales Model

8.5.2 Sales Channel

8.5.3 AI-based Antibody Development Platform Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. AI-based Antibody Development Platform Market Trends

Table 2. AI-based Antibody Development Platform Market Drivers & Opportunity

Table 3. AI-based Antibody Development Platform Market Challenges

Table 4. AI-based Antibody Development Platform Market Restraints

Table 5. Global AI-based Antibody Development Platform Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global AI-based Antibody Development Platform Revenue Market Share by Company (2019-2024)

Table 7. Key Companies AI-based Antibody Development Platform Manufacturing Base Distribution and Headquarters

Table 8. Key Companies AI-based Antibody Development Platform Product Type

Table 9. Key Companies Time to Begin Mass Production of AI-based Antibody Development Platform

Table 10. Global AI-based Antibody Development Platform Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AI-based Antibody Development Platform as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global AI-based Antibody Development Platform Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global AI-based Antibody Development Platform Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global AI-based Antibody Development Platform Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global AI-based Antibody Development Platform Sales Market Share in Value by Type (2019-2024)

Table 17. Global AI-based Antibody Development Platform Sales Market Share in Value by Type (2025-2030)

Table 18. Global AI-based Antibody Development Platform Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global AI-based Antibody Development Platform Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global AI-based Antibody Development Platform Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global AI-based Antibody Development Platform Sales Market Share in Value by Application (2019-2024)

Table 22. Global AI-based Antibody Development Platform Sales Market Share in Value by Application (2025-2030)

Table 23. Global AI-based Antibody Development Platform Sales Value by Region, (2019 VS 2023 VS 2030) & (US$ Million)

Table 24. Global AI-based Antibody Development Platform Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global AI-based Antibody Development Platform Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global AI-based Antibody Development Platform Sales Value by Region (2019-2024) & (%)

Table 27. Global AI-based Antibody Development Platform Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions AI-based Antibody Development Platform Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions AI-based Antibody Development Platform Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions AI-based Antibody Development Platform Sales Value, (2025-2030) & (US$ Million)

Table 31. Kyinno Biotechnolog Basic Information List

Table 32. Kyinno Biotechnolog Description and Business Overview

Table 33. Kyinno Biotechnolog AI-based Antibody Development Platform Products, Services and Solutions

Table 34. Revenue (US$ Million) in AI-based Antibody Development Platform Business of Kyinno Biotechnolog (2019-2024)

Table 35. Kyinno Biotechnolog Recent Developments

Table 36. XtalPi Inc Basic Information List

Table 37. XtalPi Inc Description and Business Overview

Table 38. XtalPi Inc AI-based Antibody Development Platform Products, Services and Solutions

Table 39. Revenue (US$ Million) in AI-based Antibody Development Platform Business of XtalPi Inc (2019-2024)

Table 40. XtalPi Inc Recent Developments

Table 41. DenovAI Biotech Basic Information List

Table 42. DenovAI Biotech Description and Business Overview

Table 43. DenovAI Biotech AI-based Antibody Development Platform Products, Services and Solutions

Table 44. Revenue (US$ Million) in AI-based Antibody Development Platform Business of DenovAI Biotech (2019-2024)

Table 45. DenovAI Biotech Recent Developments

Table 46. immunitoAI Private Limited Basic Information List

Table 47. immunitoAI Private Limited Description and Business Overview

Table 48. immunitoAI Private Limited AI-based Antibody Development Platform Products, Services and Solutions

Table 49. Revenue (US$ Million) in AI-based Antibody Development Platform Business of immunitoAI Private Limited (2019-2024)

Table 50. immunitoAI Private Limited Recent Developments

Table 51. EVQLV Basic Information List

Table 52. EVQLV Description and Business Overview

Table 53. EVQLV AI-based Antibody Development Platform Products, Services and Solutions

Table 54. Revenue (US$ Million) in AI-based Antibody Development Platform Business of EVQLV (2019-2024)

Table 55. EVQLV Recent Developments

Table 56. Creative Biolabs Basic Information List

Table 57. Creative Biolabs Description and Business Overview

Table 58. Creative Biolabs AI-based Antibody Development Platform Products, Services and Solutions

Table 59. Revenue (US$ Million) in AI-based Antibody Development Platform Business of Creative Biolabs (2019-2024)

Table 60. Creative Biolabs Recent Developments

Table 61. Key Raw Materials Lists

Table 62. Raw Materials Key Suppliers Lists

Table 63. AI-based Antibody Development Platform Downstream Customers

Table 64. AI-based Antibody Development Platform Distributors List

Table 65. Research Programs/Design for This Report

Table 66. Key Data Information from Secondary Sources

Table 67. Key Data Information from Primary Sources

Table 68. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. AI-based Antibody Development Platform Product Picture

Figure 2. Global AI-based Antibody Development Platform Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global AI-based Antibody Development Platform Sales Value (2019-2030) & (US$ Million)

Figure 4. AI-based Antibody Development Platform Report Years Considered

Figure 5. Global AI-based Antibody Development Platform Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Companies in the World: Market Share by AI-based Antibody Development Platform Revenue in 2023

Figure 7. AI-based Antibody Development Platform Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Antibody Generation and Screening Picture

Figure 9. Discovery and Target Recognition Picture

Figure 10. Engineering and Optimization Picture

Figure 11. Other Picture

Figure 12. Global AI-based Antibody Development Platform Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global AI-based Antibody Development Platform Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Pharmaceutical

Figure 15. Product Picture of Biotechnology

Figure 16. Product Picture of Academic Research

Figure 17. Product Picture of Others

Figure 18. Global AI-based Antibody Development Platform Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global AI-based Antibody Development Platform Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America AI-based Antibody Development Platform Sales Value (2019-2030) & (US$ Million)

Figure 21. North America AI-based Antibody Development Platform Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 23. Europe AI-based Antibody Development Platform Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 25. Asia Pacific AI-based Antibody Development Platform Sales Value by Region (%), 2023 VS 2030

Figure 26. South America AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 27. South America AI-based Antibody Development Platform Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa AI-based Antibody Development Platform Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions AI-based Antibody Development Platform Sales Value (%), (2019-2030)

Figure 31. United States AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

Figure 33. United States AI-based Antibody Development Platform Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe AI-based Antibody Development Platform Sales Value by Application (%), 2023 VS 2030

Figure 37. China AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 38. China AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

Figure 39. China AI-based Antibody Development Platform Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan AI-based Antibody Development Platform Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea AI-based Antibody Development Platform Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia AI-based Antibody Development Platform Sales Value by Application (%), 2023 VS 2030

Figure 49. India AI-based Antibody Development Platform Sales Value, (2019-2030) & (US$ Million)

Figure 50. India AI-based Antibody Development Platform Sales Value by Type (%), 2023 VS 2030

Figure 51. India AI-based Antibody Development Platform Sales Value by Application (%), 2023 VS 2030

Figure 52. AI-based Antibody Development Platform Industrial Chain

Figure 53. AI-based Antibody Development Platform Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

Figure 57. Key Executives Interviewed

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global AI-based Antibody Development Platform market? zhanKai

The top companies in the global AI-based Antibody Development Platform market are Kyinno Biotechnolog、XtalPi Inc、DenovAI Biotech.

Related Reports

Global AI-based Antibody Development Platform Market Outlook, In‑Depth Analysis & Forecast to 2032
The global AI-based Antibody Development Platform market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 127
USD 4900.00
(Single User License)
Global AI-based Antibody Development Platform Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global AI-based Antibody Development Platform market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 79
USD 4250.00
(Single User License)
AI-based Antibody Development Platform - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for AI-based Antibody Development Platform was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-19
Pages: 89
USD 3950.00
(Single User License)
Global AI-based Antibody Development Platform Market Research Report 2026
The global AI-based Antibody Development Platform market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-14
Pages: 109
USD 2900.00
(Single User License)
Global AI-based Antibody Development Platform Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global AI-based Antibody Development Platform market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 78
USD 4250.00
(Single User License)
Global AI-based Antibody Development Platform Market Outlook, In‑Depth Analysis & Forecast to 2031
The global AI-based Antibody Development Platform market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-05
Pages: 118
USD 4900.00
(Single User License)
AI-based Antibody Development Platform - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for AI-based Antibody Development Platform was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-11
Pages: 83
USD 3950.00
(Single User License)
Global AI-based Antibody Development Platform Market Research Report 2025
The global market for AI-based Antibody Development Platform was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-03-11
Pages: 76
USD 2900.00
(Single User License)
Global and United States AI-based Antibody Development Platform Market Report & Forecast 2024-2030
A critical aspect of a successful pandemic response is expedient antibody discovery, manufacturing and deployment of effective lifesaving treatments to patients around the world. However, typical drug discovery and development is a lengthy multi-step process that must align drug efficacy with multiple developability criteria and can take years to complete. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of therapeutics, increasing their activity and safety as well as decreasing their development time and manufacturing costs. Artificial intelligence stands at the forefront of transforming antibody development. AI and machine learning (ML) algorithms can analyze vast datasets, uncover patterns, and predict outcomes with a speed and accuracy unattainable by human researchers.
Published Date: 2024-06-15
Pages: 101
USD 4350.00
(Single User License)
Global AI-based Antibody Development Platform Market Research Report 2024
A critical aspect of a successful pandemic response is expedient antibody discovery, manufacturing and deployment of effective lifesaving treatments to patients around the world. However, typical drug discovery and development is a lengthy multi-step process that must align drug efficacy with multiple developability criteria and can take years to complete. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of therapeutics, increasing their activity and safety as well as decreasing their development time and manufacturing costs. Artificial intelligence stands at the forefront of transforming antibody development. AI and machine learning (ML) algorithms can analyze vast datasets, uncover patterns, and predict outcomes with a speed and accuracy unattainable by human researchers.
Published Date: 2024-06-15
Pages: 76
USD 2900.00
(Single User License)

Global AI-based Antibody Development Platform Market Outlook, In‑Depth Analysis & Forecast to 2032
The global AI-based Antibody Development Platform market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 127
USD 4900.00 (Single User License)
Global AI-based Antibody Development Platform Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global AI-based Antibody Development Platform market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 79
USD 4250.00 (Single User License)
AI-based Antibody Development Platform - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for AI-based Antibody Development Platform was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-01-19
Pages: 89
USD 3950.00 (Single User License)
Global AI-based Antibody Development Platform Market Research Report 2026
The global AI-based Antibody Development Platform market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-01-14
Pages: 109
USD 2900.00 (Single User License)
Global AI-based Antibody Development Platform Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global AI-based Antibody Development Platform market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 78
USD 4250.00 (Single User License)
Global AI-based Antibody Development Platform Market Outlook, In‑Depth Analysis & Forecast to 2031
The global AI-based Antibody Development Platform market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-05
Pages: 118
USD 4900.00 (Single User License)
AI-based Antibody Development Platform - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for AI-based Antibody Development Platform was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-11
Pages: 83
USD 3950.00 (Single User License)
Global AI-based Antibody Development Platform Market Research Report 2025
The global market for AI-based Antibody Development Platform was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-03-11
Pages: 76
USD 2900.00 (Single User License)
Global and United States AI-based Antibody Development Platform Market Report & Forecast 2024-2030
A critical aspect of a successful pandemic response is expedient antibody discovery, manufacturing and deployment of effective lifesaving treatments to patients around the world. However, typical drug discovery and development is a lengthy multi-step process that must align drug efficacy with multiple developability criteria and can take years to complete. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of therapeutics, increasing their activity and safety as well as decreasing their development time and manufacturing costs. Artificial intelligence stands at the forefront of transforming antibody development. AI and machine learning (ML) algorithms can analyze vast datasets, uncover patterns, and predict outcomes with a speed and accuracy unattainable by human researchers.
Published: 2024-06-15
Pages: 101
USD 4350.00 (Single User License)
Global AI-based Antibody Development Platform Market Research Report 2024
A critical aspect of a successful pandemic response is expedient antibody discovery, manufacturing and deployment of effective lifesaving treatments to patients around the world. However, typical drug discovery and development is a lengthy multi-step process that must align drug efficacy with multiple developability criteria and can take years to complete. In this context, artificial intelligence (AI), and especially machine learning (ML), have great potential to accelerate and improve the optimization of therapeutics, increasing their activity and safety as well as decreasing their development time and manufacturing costs. Artificial intelligence stands at the forefront of transforming antibody development. AI and machine learning (ML) algorithms can analyze vast datasets, uncover patterns, and predict outcomes with a speed and accuracy unattainable by human researchers.
Published: 2024-06-15
Pages: 76
USD 2900.00 (Single User License)